oteracil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
uracil type antineoplastics 2002 937-13-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • potassium oxonate
  • oxonic acid potassium salt
  • oteracil
  • 5-Azaorotic acid
  • oxonic acid
  • oteracil potassium
Antagonist of urate oxidase.
  • Molecular weight: 157.09
  • Formula: C4H3N3O4
  • CLOGP: -2.13
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 107.86
  • ALOGS: -1.34
  • ROTB: 1

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 14, 2011 EMA Nordic Group BV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bone marrow failure 83.65 41.97 29 1064 30086 53317887
Osteonecrosis of jaw 60.47 41.97 24 1069 36122 53311851
Malignant neoplasm progression 59.38 41.97 29 1064 71512 53276461
Myelosuppression 50.12 41.97 16 1077 12812 53335161
Decreased appetite 46.65 41.97 37 1056 214937 53133036
Hereditary motor and sensory neuropathy 43.48 41.97 6 1087 71 53347902

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 96.79 32.87 61 2459 64940 32446066
Myelosuppression 94.07 32.87 35 2485 11641 32499365
Bone marrow failure 90.45 32.87 45 2475 30359 32480647
Decreased appetite 72.85 32.87 75 2445 160738 32350268
Disseminated intravascular coagulation 65.05 32.87 33 2487 23143 32487863
Disease progression 57.36 32.87 50 2470 86812 32424194
Gastric perforation 52.15 32.87 15 2505 2218 32508788
Malignant neoplasm progression 47.45 32.87 43 2477 78453 32432553
Tumour perforation 44.29 32.87 9 2511 304 32510702
Neuropathy peripheral 44.24 32.87 41 2479 76941 32434065
Palmar-plantar erythrodysaesthesia syndrome 42.92 32.87 22 2498 15727 32495279
Haematotoxicity 42.69 32.87 17 2503 6759 32504247
Necrotising fasciitis 40.51 32.87 14 2506 3755 32507251
Diarrhoea 39.76 32.87 87 2433 364715 32146291
Perforation bile duct 37.09 32.87 6 2514 53 32510953
Hepatic atrophy 35.47 32.87 7 2513 203 32510803
Granulocyte-colony stimulating factor level increased 34.29 32.87 5 2515 20 32510986
Platelet count decreased 33.94 32.87 43 2477 114548 32396458
Hiccups 33.42 32.87 16 2504 9879 32501127
Bacterial translocation 33.29 32.87 7 2513 280 32510726

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Malignant tumor of stomach indication 363349007 DOID:10534

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.67 acidic
pKa2 10.06 acidic
pKa3 0.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Uridine 5'-monophosphate synthase Enzyme INHIBITOR SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
2207-75-2 SECONDARY_CAS_RN
C0030032 UMLSCUI
CHEBI:80230 CHEBI
OXC PDB_CHEM_ID
CHEMBL181932 ChEMBL_ID
DB03209 DRUGBANK_ID
4604 PUBCHEM_CID
7729 INN_ID
C489337 MESH_SUPPLEMENTAL_RECORD_UI
5VT6420TIG UNII
013265 NDDF
015260 NDDF
D010094 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None